Trial Profile

A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elotuzumab (Primary) ; Lenalidomide (Primary) ; Bortezomib; Dexamethasone
Indications Multiple myeloma
Focus Therapeutic Use
Acronyms GMMG-HD6

10 Dec 2024 Results (Between 06/2015 and 09/2017, n=564 patients) investigating prognostic impact of clonal heterogeneity identified by fluorescence in situ hybridization , presented at the 66th American Society of Hematology Annual Meeting and Exposition
10 Dec 2024 Results assessing long-term follow-up, presented at the 66th American Society of Hematology Annual Meeting and Exposition.
12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com